Biotherapeutics is one of the fastest growing areas in the pharmaceutical industry - within which antibodies make up the predominant class. Many of these antibody therapeutics are generated in non-human systems and have demonstrated to be immunogenic and induce human immune responses when injected into patients. This results in neutralization of its therapeutic properties and limits the application of such antibodies in treatment of human disease. My work involves data mining of antibody next-generation sequencing data to assist in humanization methods and reduce immunogenecity of antibody therapeutics.